Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
Detailed guidance document from FDA and regulatory agencies.
Document Details
Unknown
July 28, 2005
December 1, 2018
a0e9555e-44bd-4cf3-bfa3-7f67f0d88a6f
Related Documents
Role of HIV Drug Resistance Testing in Antiretroviral Drug Development
UnknownOctober 31, 2007Center for Drug Evaluation and Research
Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children
UnknownMarch 6, 2007Center for Drug Evaluation and Research
Nonclinical Safety Evaluation of Pediatric Drug Products
UnknownFebruary 15, 2006Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.